Earnings before interest, taxes, depreciation, and amortisation rose to £8.7m (€10.32m) from £5.2m (€6.2m) in the same period in 2023.
Hvivo also reported 30.6pc rise in revenues in the first half of the year.
The London-listed organisation reported revenues of £35.6m (€42.23m) in the first half, according to a trading update published today.
The firm runs drug trials known as challenge studies from its London clinics.
Hvivo had a weighted contracted orderbook of £71m at the end of June, down from £78m at the same time last year.
The company’s facility in Canary Wharf also opened in the period, while a record number of volunteers were inoculated in the first half across six challenge trials and five challenge agents.
Hvivo also reported that it was able to use its multiple quarantine facilities to complete a number of projects ahead of schedule, which also contributed to revenue growth.
A £6.3m contract focused on Human Rhinovirus – the virus that causes the common cold – was signed with a biotech client in the first half, as well as a £2.5m Omicron characterisation study contract.
Earlier this month, the company also cancelled trading on the Euronext Growth index in Dublin to consolidate trading of its stock to its primary listing on the AIM market of the London Stock Exchange.
Hvivo reaffirmed revenue guidance of £62m for the year. Ebitda margins are also anticipated to be at the upper end of market expectations, which are currently 22pc – 24pc.
The company also reported that with 100pc of revenue guidance for this year is already contracted, with “good visibility” into 2025.
It added that it has short to medium term potential opportunities valued at around £40m.
“We continue to expand our pipeline, not only in human challenge trials but also in our new revenue streams including clinical site studies, standalone laboratory services, and volunteer / patient recruitment.” chief executive Yamin ‘Mo’ Khan said.
“Operational efficiencies are set to continue to improve with the expansion of our services, improved automation, and the move to our new facility in Canary Wharf.”